Sign in

    Danielle Brill Bongero

    Research Analyst at Raymond James

    Danielle Brill Bongero is a Research Analyst at Raymond James & Associates, specializing in healthcare and biotechnology equity research. She currently covers 35 stocks, including companies such as Harmony Biosciences and Sarepta Therapeutics, and maintains a 49.31% success rate with a 4.01-star performance rating based on published analyst performance metrics. Danielle began her analyst career at Piper Sandler before joining Raymond James in 2020, and she has also been affiliated with Truist Securities. She holds FINRA registration CRD# 6543815 and is licensed for relevant securities activities, demonstrating robust professional qualifications in financial services.

    Danielle Brill Bongero's questions to PTC THERAPEUTICS (PTCT) leadership

    Danielle Brill Bongero's questions to PTC THERAPEUTICS (PTCT) leadership • Q3 2024

    Question

    Danielle Brill Bongero of Raymond James sought clarification on why the Translarna NDA filing is considered a resubmission rather than a new NDA, despite including new data from Study 041.

    Answer

    CEO Matthew Klein explained the procedural history: the original NDA was filed in 2016 and received a Complete Response Letter (CRL) that mandated an additional trial. Because Study 041 was conducted specifically to address the deficiency cited in that CRL, the current filing is technically a resubmission of the original application.

    Ask Fintool Equity Research AI